Clinuvel Pharmaceuticals (ASX: CUV) aims to make all its divisions profitable in 5 years

4 min read | October 19, 2023 10:53 AM AEDT | By Team Kalkine Media

Google News:

Clinuvel Pharmaceuticals (ASX: CUV) aims to make all its divisions profitable in 5 years — Image source: Pixabay

Recent News

Why Is Insider Activity Putting Lion Rock Minerals Back in Focus?

Should Investors Be Concerned About Insider Selling at Clever Culture...

Can Lendlease’s Australia-First Strategy Rewrite Its Future?

3 ASX ETFs That Could Shape the Next Decade

Make Kalkine Media
My Trusted Source

Highlights

Clinuvel is an international pharmaceutical firm which is focused on developing and marketing treatments for a range of disorders

Since FY2017, the company has been revenue and cashflow positive

In the coming five years, the company intends to make all divisions profitable

Clinuvel Pharmaceuticals Limited (ASX:CUV) is an international pharmaceutical company which is engaged in the development and commercialization of treatments for patients with acute, genetic, systematic, metabolic and life-threatening disorders. Also, the company offers healthcare solutions to the public.

In the financial year 2023, the company reported a 23.92% YoY growth in total revenue to AUD83.01 million, a 32.80% YoY rise in net profit before income tax to AUD 45.57 million and a 29% YoY jump in cash reserves to AUD 156.8 million. The demand for its lead therapy – SCENESSE- drove the yearly revenue.

Since FY17, the company has continuously delivered positive profits and cash flows.

Top 10 shareholders of CUV

The top 10 shareholders of CUV have around 27.79% shareholding in the company, while the top four have nearly 19.58% stake. Wolgen (Philippe Jacques) and Ender 1, LLC have the highest shareholding in the company, with a stake of ~6.32% and ~5.24%, respectively.

Recent business update

Through an ASX filing dated 18 October 2023, the company shared that it has commenced the global Phase III vitiligo study with SCENESSE administered as a treatment to the first patient with vitiligo. The study will comprise around 200 adult and adolescent patients with vitiligo and darker skin types.

Outlook

The company is focused on diversifying its activities and fueling its profitability through its multiple divisions. In the coming five years, the company expects to make its four divisions – healthcare solutions, pharmaceuticals, branding & marketing and manufacturing & communications-profitable.

CUV plans to enter into in-licensing contracts and undertake acquisition to add complementary technologies further.

Furthermore, the focus is on developing three PhotoCosmetic product lines to be marketed across the globe.

Share performance of CUV

Shares of CUV closed 0.63% higher at AUD 15.96 apiece on 18 October 2023. With this, CUV’s share price dropped by 40.18% in the last nine months and increased by 0.50% in the last one week.

The 52-week high of CUV is AUD 8.72 apiece, recorded on 30 January 2023, and the 52-week low is AUD 13.97 apiece, recorded on 4 October 2023.

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 18 October 2023. The reference data in this report has been partly sourced from EODHD/Others.

Disclaimer

This article has been prepared by Kalkine Media, echoed on the website kalkinemedia.com/au and associated pages, based on the information obtained and collated from the subscription reports prepared by Kalkine Pty. Ltd. [ABN 34 154 808 312; AFSL no. 425376] on Kalkine.com.au (and associated pages). The principal purpose of the content is to provide factual information only for educational purposes. None of the content in this article, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video is or is intended to be, advisory in nature. The content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including but not limited to, in respect of any particular security, transaction, or investment strategy, and must not be relied upon by you as such. The content is provided without any express or implied warranties of any kind. Kalkine Media, and its related bodies corporate, agents, and employees (Kalkine Group) cannot and do not warrant the accuracy, completeness, timeliness, merchantability, or fitness for a particular purpose of the content or the website, and to the extent permitted by law, Kalkine Group hereby disclaims any and all such express or implied warranties. Kalkine Group shall NOT be held liable for any investment or trading losses you may incur by using the information shared on our website.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.